B2i Digital

Financial documents speak volumes before a single number is read. Regulatory filings’ layout, typography, and production quality create a first impression that can either reinforce or undermine investor confidence. Content and results matter, of course, but market perception is built on attention to detail. The Nuvo Group transforms complex financial data into polished, compliant documents that strengthen investor confidence while ensuring regulatory precision. The Nuvo Group is a B2i Digital Featured Expert. Learn more about the company by visiting their in-depth profile here: https://lnkd.in/e8tSR-uq What sets The Nuvo Group apart in financial printing is their people-centric approach. Their team rejects the “assembly line” mentality, treating every order as custom work tailored to specific client needs. This blend of technical expertise and personalized service creates financial documents that serve both compliance requirements and communication goals. The Nuvo Group’s comprehensive financial printing services include: - Tailored document design for annual reports, proxies, and presentations - Comprehensive services including creation, editing, printing, and mailing - Expert handling of compliance documents, M&A materials, and private equity reports - Time-sensitive production for transactions and regulatory deadlines - Advanced document composition exceeding traditional PDF/HTML standards In an environment where filing deadlines are unforgiving, and accuracy is non-negotiable, The Nuvo Group’s approach combines cutting-edge technology with deep industry knowledge to deliver meaningful results. Their compliance, transactions, private equity, and investor relations specialists work together to produce documents that meet exacting standards while communicating your corporate story effectively. Led by Managing Partners Tony Barletta and Frederick M Jaffe, The Nuvo Group is a trusted partner for public companies, investment banks, and law firms nationwide. Their reputation as a leader in regulatory financial solutions is built on accuracy, compliance expertise, and client-first service. For updates on The Nuvo Group and other Featured Experts, visit B2i Digital. #FinancialPrinting #SECFilings #CorporateCommunications #TheNuvoGroup #B2iDigital

Ladenburg Thalmann is pleased to welcome investors, company executives, and industry leaders to the Innovation EXPO25 on Wednesday, May 21, 2025, at Convene, 101 Park Avenue in New York City. This in-person event will feature presentations from approximately 50 public and private companies applying AI in transformative ways across sectors. With three simultaneous presentation tracks, one-on-one and small group meetings, and live product demonstrations, the agenda is designed to foster meaningful conversations and help uncover compelling investment ideas. We look forward to a day of engagement, discovery, and connection, culminating in a cocktail reception sponsored by The Money Channel. For those unable to attend in person, select presentations will be available via livestream to ensure broader access to shared insights. ·        Learn more about the event: https://lnkd.in/ezb-pQvF ·        Investors who wish to attend may request registration: https://lnkd.in/esJ9zrqJ Note that registration requests are subject to approval by a representative of Ladenburg. Ladenburg Thalmann looks forward to your participation in what promises to be a fascinating glimpse into how AI is transforming technology, business, finance, and investing. #InnovationEXPO25 #LadenburgThalmann #AI #TechInvesting #InstitutionalInvestors #CapitalMarkets

Intelligent Bio Solutions (Nasdaq: INBS) today announced the launch of new localized websites in Arabic, Italian, and Spanish, supporting commercial access to high-growth regions across Europe, the Middle East, and Latin America. The multilingual rollout is part of a broader business localization strategy aligned with INBS’s international expansion goals. Intelligent Bio Solutions is a B2i Digital Featured Company. View its comprehensive profile at https://lnkd.in/gCF9hkFm Highlights from today’s announcement include: ·   The new sites are designed to strengthen lead generation and distributor relationships in regions with a combined population of over 1.4 billion people. ·   The effort complements INBS’s multilingual fingerprint drug testing system, which has already generated strong interest in non-English-speaking markets. ·   With increasing workplace safety regulations, demand is expected to grow in Latin America and GCC countries. The Latin American drug testing market is projected to reach $1.1 billion by 2030. ·   The new websites, accessible in Arabic, Italian, Spanish, and English, are available at https://lnkd.in/ei4yw4_q Harry Simeonidis, President & CEO of Intelligent Bio Solutions, commented, “This is not just a translation project; it’s a commercial growth engine. By localizing our online presence and sales infrastructure to make it ready for use by customers across the globe, we are building scalable access to high-potential markets. These initiatives are the foundation for strengthening distributor relationships, increasing lead generation, and facilitating faster market penetration worldwide.” See the full announcement here: https://lnkd.in/eBinyMdk Led by CEO Harry Simeonidis and CFO Spiro Sakiris, INBS is committed to revolutionizing drug screening with its hygienic, rapid, and cost-effective fingerprint sweat-based solution. The company’s non-invasive, patented technology enables on-site drug screening in just minutes, offering many advantages over traditional testing methods. INBS serves a broad range of industries, including workplace safety, law enforcement, drug treatment, and forensics, with a growing global footprint of 400+ accounts across 19 countries. The company’s skilled global management team includes Anna Turkington, Ghanshyam Poudel, Taylor Doherty, Daniel Brown, Doug Heath, Sugam Pokharel, Victoria Gavrilenko, Rafael da Luz, MBA, Callistus Sequeira, Derek Mapoli, and Peter Passaris. For investor inquiries, visit https://investors.ibs.inc or contact Valter Pinto at INBS@kcsa.com, KCSA Strategic Communications. #IntelligentBioSolutions #INBS #B2iDigital #DrugScreening #Localization

We are excited to share that Stocktwits is a proud bronze sponsor for the upcoming Ladenburg Thalmann Technology Innovation EXPO25 on May 21, 2025 at Convene 101 Park Avenue in New York City. Stocktwits is the premier social media platform dedicated to TradFi and DeFi investors and traders. With an active community of over 10 million users, Stocktwits has established itself as a leading voice in the investing world. Driven by the mission to help investors enhance their returns, Stocktwits offers a rich ecosystem of community interaction, data, content, and tools that empower investors to connect, learn, and have fun in the process. For more information, visit stocktwits.com Ladenburg Thalmann Technology Innovation EXPO25 is a B2i Digital Featured Conference. See details and submit a registration request at https://lnkd.in/e8QjgMuh Ladenburg's focused, high-impact event will showcase approximately 50 cutting-edge technology companies harnessing AI in transformative ways. The conference format includes three presentation tracks, personalized one-on-one meetings, and live product demonstrations through the innovative 'Ladenburg Expo format.' This approach has proven highly effective at previous Ladenburg Thalmann events, creating an environment where sophisticated investors can engage directly with pioneering technology leaders. For more information and to submit a registration request, visit: https://lnkd.in/e8QjgMuh Thank you to the team at Ladenburg Thalmann for organizing this event!

We want to welcome our B2i Digital Featured Company Applied Energetics, Inc. to the upcoming Ladenburg Thalmann Technology Innovation EXPO25 on May 21, 2025 at Convene 101 Park Avenue in New York City. Applied Energetics, Inc. specializes in advanced laser and photonics systems, particularly fiber-based ultrashort pulse (USP) laser technologies. With 26 patents and 8 patents pending, Applied Energetics' proprietary architecture enables orders of magnitude size-weight-power reductions, a key differentiator when compared with traditional continuous wave (CW) laser technology with larger footprints. AE's powerful, dual-use systems are designed for integration and deployment on numerous potential defense platforms for the delivery of high intensity, ultrashort pulses of light to disable or destroy targets. These technologies have applications in both national security and commercial markets.Today, AE's USP optical technologies are being designed to offer flexibility and power for complex missions in national security such as enhancing layered defense strategies to counter complex threats. Applications include counter-ISR (intelligence, surveillance, and reconnaissance), counter-drone, and others. Ladenburg Thalmann Technology Innovation EXPO25 is a B2i Digital Featured Conference. See details and submit a registration request at https://lnkd.in/e8QjgMuh Ladenburg's focused, high-impact event will showcase approximately 50 cutting-edge technology companies harnessing AI in transformative ways. The conference format includes three presentation tracks, personalized one-on-one meetings, and live product demonstrations through the innovative 'Ladenburg Expo format.' This approach has proven highly effective at previous Ladenburg Thalmann events, creating an environment where sophisticated investors can engage directly with pioneering technology leaders. For more information and to submit a registration request, visit: https://lnkd.in/e8QjgMuh Thank you to the team at Ladenburg Thalmann for organizing this event!

OS Therapies (NYSE-A: OSTX) announced the issuance of a new U.S. patent that extends commercial manufacturing exclusivity for its lead asset, OST-HER2, and the broader listeria-based immunotherapy platform into 2040. The patent protects key processes and formulations used in developing treatments for rare pediatric cancer osteosarcoma and other HER2-positive cancers. OS Therapies is a B2i Digital Featured Company. View their comprehensive profile at https://lnkd.in/epFNRZQB Highlights from today’s announcement include: - U.S. Patent No. 12,239,738 covers the commercial manufacturing of OST-HER2 and the entire listeria monocytogenes cancer immunotherapy platform, securing market exclusivity through 2040. - The patent supports potential FDA approval of OST-HER2 in osteosarcoma and positions the company to expand into additional HER2-positive cancers and metastatic disease. - OS Therapies’ pipeline includes three clinical-stage and eight pre-clinical assets designed to advance the standard of care across multiple cancer types. Paul Romness, CEO of OS Therapies, noted, “The issuance of this patent covering commercial manufacturing for the entire listeria monocytogenes platform breathes new life into our pipeline, giving us the exclusive ability to develop this exciting field of cancer immunotherapy. Potential FDA approval of OST-HER2 in Osteosarcoma would bring a Priority Review Voucher valued at least $150 million. This non-dilutive capital will allow us to expand OST-HER2 use into metastatic & frontline osteosarcoma, and other HER2 positive cancers.” See the full announcement: https://lnkd.in/eJEu_qVY OST-HER2 is a listeria-based immunotherapy designed to stimulate an immune response against HER2-expressing cancer cells. It has demonstrated statistically significant results in recurrent, fully resected, lung metastatic osteosarcoma and has received RPDD, Fast Track, and Orphan Drug designations from the FDA. A Biologics License Application (BLA) is planned for submission in 2025. Led by CEO Paul Romness and an experienced executive team that includes Christopher Acevedo (CFO), Robert Petit (Chief Medical and Scientific Officer), John Doll (Chief of Staff), and Gerald Commissiong (Chief Business Officer), OS Therapies is focused on driving its pipeline forward to deliver potentially transformative treatments for osteosarcoma and other hard-to-treat cancers. Learn more about OS Therapies’ work at https://lnkd.in/eMc3JKG6 and visit B2i Digital for updates. For investor-related questions, please visit OS Therapies’ Investor Relations page or email irpr@ostherapies.com.

We are excited to share that CBIZ is a proud bronze sponsor for the upcoming Ladenburg Thalmann Technology Innovation EXPO25 on May 21, 2025 at Convene 101 Park Avenue in New York City. CBIZ, Inc. (NYSE:CBZ) is a publicly traded, leading professional services advisor to middle market businesses and organizations nationwide. With unmatched industry knowledge and expertise in accounting, tax, advisory, benefits, insurance and technology, CBIZ delivers forward-thinking insights and actionable solutions to help you anticipate next steps and accelerate growth. We help your organization navigate challenges, turn risk into opportunity and drive sustainable, long-term excellence — where you are today and wherever you want to grow. Our 10,000+ team members across 160+ locations in 22 major markets provide top-tier industry expertise with local delivery, relationships and support. Ladenburg Thalmann Technology Innovation EXPO25 is a B2i Digital Featured Conference. See details and submit a registration request at https://lnkd.in/e8QjgMuh Ladenburg's focused, high-impact event will showcase approximately 50 cutting-edge technology companies harnessing AI in transformative ways. The conference format includes three presentation tracks, personalized one-on-one meetings, and live product demonstrations through the innovative 'Ladenburg Expo format.' This approach has proven highly effective at previous Ladenburg Thalmann events, creating an environment where sophisticated investors can engage directly with pioneering technology leaders. For more information and to submit a registration request, visit: https://lnkd.in/e8QjgMuh Thank you to the team at Ladenburg Thalmann for organizing this event!

We are thrilled to announce The Nuvo Group as a Gold Sponsor at our upcoming LA Summit in June! The Nuvo Group provides financial printing, digital publishing and EDGAR SEC electronic filing services to some of the world's most respected financial institutions. We possess the tools, team and advanced technologies to ensure an exceptional customer experience — ease of process, rapid execution, regulatory compliance and, of course, uncompromising accuracy. Our Mission & Vision To consistently perform in ways that make our customers’ jobs easier, and their printing and filing faster To leverage the most experienced talent, effective tools and advanced technologies in financial printing, digital publishing and EDGAR SEC filing today in order to simplify, accelerate and enhance the end product we proudly deliver to our customers — on time, in format and on budget. To lead in the design and development of groundbreaking services, solutions and support systems, innovations that redefine the industry of financial printing, digital publishing and EDGAR SEC filing and deliver more tangible value and responsiveness to customers — compressed lead times, error-free documents, streamlined production and reduced cost. Proud to be named one of Inc 5000's Fastest Growing Private Companies Arti Gandhi Joseph Contorno Tony Barletta Frederick M Jaffe Melissa Fincher Scott Lam Kia Besharat Nima Besharat Raphael Yeung, CFA Jane Mark

We are continuing to get in front of all stakeholders! Go team Unicycive Therapeutics.

We want to welcome Focus Universal to the upcoming Ladenburg Thalmann Technology Innovation EXPO25 on May 21, 2025 at Convene 101 Park Avenue in New York City. Focus Universal Inc. (Nasdaq: FCUV) is a provider of patented hardware and software design technologies for Internet of Things (IoT) and 5G. The company has developed five disruptive patented technology platforms with 26 patents and patents pending in various phases and eight trademarks pending in various phases to solve the major problems facing hardware and software design and production within the industry today. The company is also developing and designing a software to streamline SEC financial reporting for financial reporting and tax firms. This is focused on streamlining the entire SEC financial reporting process for attorneys, accounting firms, and other financial reporting professionals. Our goal is that with a single click, our software automatically retrieves financial data from external accounting systems and generates consolidated financial statements and SEC reports —all within just a few minutes. Our developers are automating to eliminate human involvement when it comes to manually updating the numbers. These technologies combined to have the potential to reduce manpower costs, expense costs, product development timelines and energy usage while increasing range, speed, efficiency, and security. Focus currently trades on the Nasdaq Markets. We look forward to seeing the continued results from Desheng Wang and the entire team. Ladenburg Thalmann Technology Innovation EXPO25 is a B2i Digital Featured Conference. See details and submit a registration request at https://lnkd.in/e8QjgMuh Ladenburg's focused, high-impact event will showcase approximately 50 cutting-edge technology companies harnessing AI in transformative ways. The conference format includes three presentation tracks, personalized one-on-one meetings, and live product demonstrations through the innovative 'Ladenburg Expo format.' This approach has proven highly effective at previous Ladenburg Thalmann events, creating an environment where sophisticated investors can engage directly with pioneering technology leaders. For more information and to submit a registration request, visit: https://lnkd.in/e8QjgMuh Thank you to the team at Ladenburg Thalmann for organizing this event!